Russia considering large-scale production of drugs on African continent

12 November 2019

Russia may start large-scale of drugs on the African continent, that may take place within the next several years, according to recent statements made by the Russian Minister of Industry and Trade Denis Manturov as a result of the recent Russia-Africa forum, reports The Pharma Letter’s local correspondent.

According to Mr Manturov, currently the Russian government, along with some leading domestic drugmakers, are interested in the localization of certain domestic drugs in some African countries.

That could be in the form of joint productions with some leading local producers and building of production facilities from the scratch.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK